Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics of the participants. | ACEI/ARB | | | Non-user | User | | Variable | n = 1,986 | n = 1,290 | P-value: Vitamin D receptor activators | | | 0.53

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The MBD-5D study is a multicenter, 3-year, prospective, observational study involving maintenance hemodialysis patients with secondary hyperparathyroidism.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients

Observational study · PLoS ONE · 2015

Original publication title

Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients

Suguru Yamamoto; Ryo Kido; Yoshihiro Onishi; Shingo Fukuma; Tadao Akizawa; Masafumi Fukagawa; Junichiro J. Kazama; Ichiei Narita; Shunichi Fukuhara

© 2015 Yamamoto et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Use of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Patients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS inhibitors reduces the incidence of fracture in hemodialysis patients.

Source: Background

Abstract: Methods and Findings

This was a multicenter, 3-year, prospective, observational study. From 2008 to 2011, maintenance hemodialysis patients with secondary hyperparathyroidism (N = 3,276) treated with angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) at baseline were followed for a mean of 2.7 years. The association between the use of ACEI/ARB and hospitalization rate owing to fracture was examined by using Cox regression models. Effect modifications by the severity of secondary hyperparathyroidism (intact parathyroid hormone [iPTH] level), sex, and systolic blood pressure were also examined.

The incidence proportion of fracture-related hospitalization was 5.42% throughout the observation period. ACEI/ARB use was associated with a lower rate of fracture-related hospitalization (adjusted hazard ratio, 0.65; 95% confidence interval [CI], 0.45 to 0.92). This association was not significantly affected by sex (P = 0.56) or systolic blood pressure levels (P = 0.87). The hazard ratios adjusted by iPTH levels were qualitatively different, but not statistically significant (P = 0.11): 0.77 (95% CI, 0.42 to 1.39), 0.38 (95% CI, 0.20 to 0.73), 0.59 (95% CI, 0.29 to 1.21), and 1.29 (95% CI, 0.58 to 2.42) for the first, second, third and fourth quartiles of iPTH, respectively.

Source: Methods and Findings

Abstract: Conclusions

Use of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.

Source: Conclusions
Authors’ abstract

Background

Patients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS inhibitors reduces the incidence of fracture in hemodialysis patients.

Methods and Findings

This was a multicenter, 3-year, prospective, observational study. From 2008 to 2011, maintenance hemodialysis patients with secondary hyperparathyroidism (N = 3,276) treated with angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) at baseline were followed for a mean of 2.7 years. The association between the use of ACEI/ARB and hospitalization rate owing to fracture was examined by using Cox regression models. Effect modifications by the severity of secondary hyperparathyroidism (intact parathyroid hormone [iPTH] level), sex, and systolic blood pressure were also examined.

The incidence proportion of fracture-related hospitalization was 5.42% throughout the observation period. ACEI/ARB use was associated with a lower rate of fracture-related hospitalization (adjusted hazard ratio, 0.65; 95% confidence interval [CI], 0.45 to 0.92). This association was not significantly affected by sex (P = 0.56) or systolic blood pressure levels (P = 0.87). The hazard ratios adjusted by iPTH levels were qualitatively different, but not statistically significant (P = 0.11): 0.77 (95% CI, 0.42 to 1.39), 0.38 (95% CI, 0.20 to 0.73), 0.59 (95% CI, 0.29 to 1.21), and 1.29 (95% CI, 0.58 to 2.42) for the first, second, third and fourth quartiles of iPTH, respectively.

Conclusions

Use of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.

Trial Registration

ClinicalTrials.gov NCT00995163

Publication and source details

Original title: Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients

Suguru Yamamoto; Ryo Kido; Yoshihiro Onishi; Shingo Fukuma; Tadao Akizawa; Masafumi Fukagawa; Junichiro J. Kazama; Ichiei Narita; Shunichi Fukuhara

PLoS ONE · 2015

Competing Interests: The MBD-5D study was supported by research grants from Kyowa Hakko Kirin. M. F. has acted as a consultant, received honoraria, and grants (research support) from Kyowa Hakko Kirin. T. A. has acted as a consultant and received grants (research support) from Kyowa Hakko Kirin, besides of being a member of the speakers’ bureau at Kyowa Hakko Kirin. S. F. has acted as a scientific advisor for Kyowa Hakko Kirin, and has received grants (research support) from Kyowa Hakko Kirin.

The other authors have no conflicts of interest to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Conceived and designed the experiments: SY RK YO S. Fukuma TA MF JK IN S. Fukuhara. Performed the experiments: SY RK YO S. Fukuma TA MF S. Fukuhara. Analyzed the data: SY RK YO S. Fukuma S. Fukuhara. Contributed reagents/materials/analysis tools: TA MF S. Fukuhara. Wrote the paper: SY RK YO S. Fukuma TA MF JK IN S. Fukuhara.

* E-mail: yamamots@med.niigata-u.ac.jp (SY)
© 2015 Yamamoto et al2015Yamamoto et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.The MBD-5D study was supported by research grants from Kyowa Hakko Kirin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:31:21.767333+00:00

DOI: 10.1371/journal.pone.0122691 · PMC4395204